Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06129240 · ClinicalTrials.gov registry record
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
A clinical trial of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Liquidia Technologies.
- Active
- Registry status
- 80
- Enrollment target
- 18
- Study locations
NCT06129240 is a study of Pulmonary Hypertension and Interstitial Lung Disease that is active but no longer recruiting, run by Liquidia Technologies. The registered enrollment target is 80 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (87% lower). The trial reports 18 study locations across 13 states.
The verdict
NCT06129240, a study of Pulmonary Hypertension and Interstitial Lung Disease, is active but no longer recruiting, sponsored by Liquidia Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 18
- Study locations
Study Summary
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Conditions Studied
Interventions
- DRUG LIQ861
Study Locations (18)
California
- The Medical Research Group, Inc. - Fresno
- UCLA Westwood - Los Angeles
- UC Davis - Sacramento
- UCSF - San Francisco
Florida
- Advent Health - Orlando
- Tampa General Hospital Center of Research Excellence - Tampa
New York
- NYU Langone Medical Center - New York
- University of Rochester - Rochester
Arizona
- Arizona Pulmonary Specialists - Phoenix
Colorado
- National Jewish Health - Denver
Indiana
- Vincent Medical Group - Indianapolis
Michigan
- University of Michigan - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2028-02-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06129240
The ClinicalTrials.gov registry entry for NCT06129240 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (87% lower). The listed sponsor is Liquidia Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which LIQ861 is the first listed.
NCT06129240 reports 18 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06129240 about?
NCT06129240 is a clinical study titled "An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH". Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
What is the current status of trial NCT06129240?
This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2023-12-28. Estimated completion is 2028-02-08.
What conditions does trial NCT06129240 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Interstitial Lung Disease.
What interventions are being tested in trial NCT06129240?
The interventions under investigation include: LIQ861 (DRUG).
Who is sponsoring clinical trial NCT06129240?
This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06129240 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
RECRUITING
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.